Nuwe stock analysis short term

**Nuwellis (NUWE) Short-Term Stock Analysis**

1. **Technical Indicators**:
- **Moving Averages**: The 5-day moving average is $2.03, the 10-day is $1.98, and the 20-day is $1.74. This indicates a short-term downward trend, with the stock currently below these averages.
- **Recent Price Changes**: Nuwellis has experienced a significant one-week percentage change of 29.27% and a nine-day percentage change of 21.03%. However, it has also seen a recent decrease of 12.5%.
- **Short Interest**: Nuwellis has a short interest of 336,600 shares, which is 30.88% of the float. A high short interest can sometimes indicate a potential short squeeze if the stock price were to rise.

2. **Market Sentiment and News**:
- **Recent Performance**: Nuwellis reported preliminary Q3 2024 results with revenue growth of approximately $2.4 million, a 28% increase in the Pediatric category year-over-year, and an improved gross margin to 70%.
- **Analyst Ratings**: The consensus rating for Nuwellis is "Moderate Buy" with 1 buy and 1 hold ratings. The average price target is $16.00, which represents an 830.23% upside potential.
- **Short-term Price Target**: The average one-year price target is $9.18, with a range from $9.09 to $9.45. This suggests that analysts expect the stock price to increase in the medium term but may not have provided specific short-term targets.
3. **Financial Performance and Growth**:
- **Revenue and Margin**: Nuwellis has achieved 28% revenue growth in the Pediatric category year-over-year and improved gross margin to 70%, up 12.7% from the previous quarter.
- **Earnings Estimates**: Roth Capital has increased its Q3 2024 earnings per share (EPS) estimates to ($0.88) from ($0.99), indicating a potential improvement in earnings performance.
4. **Risk Considerations**:
- **Volatility**: Nuwellis has a high beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. This suggests that while it may be less volatile than some stocks, it still carries risks associated with medical device companies.
- **Short-term Fund Flow**: There is no available data on net fund flow, which could be a concern for investors looking for signs of short-term investment interest.

In conclusion, Nuwellis presents a mixed picture in the short term. While there are signs of growth and improvement in gross margin, the stock is currently trading below its short-term moving averages, and there is no available data on net fund flow. Investors should consider both the potential for growth and the lack of specific short-term indicators when analyzing Nuwellis in the short term.